

VPA10983/020/001

Aluspray 4% w/w Cutaneous Spray, Powder

Variation	Summary	Date
Vet - F.II.e.1 a) 1.	VRA-R - Vet - F.II.e.1 a) 1. - a) Qualitative and quantitative composition 1. Semi-solid and non-sterile liquid pharmaceutical forms - F.II.e.1 a) 1. Quality Changes - Container closure system - Change in immediate packaging of the finished product - Semi-solid and non-sterile liquid pharmaceutical forms	06/01/25
Vet - B35 b)	VNRA - Vet - B35 b) - b) Addition of a new specification parameter to the specification with its corresponding test method - B35 b) Changes to the quality part of the dossier: Change in the specification parameters or limits of the immediate packaging of the finished product: — addition of a new specification parameter to the specification with its corresponding test method	23/12/24
Vet - B35 b)	VNRA - Vet - B35 b) - b) Addition of a new specification parameter to the specification with its corresponding test method - B35 b) Changes to the quality part of the dossier: Change in the specification parameters or limits of the immediate packaging of the finished product: — addition of a new specification parameter to the specification with its corresponding test method	23/12/24
Vet - B35 b)	VNRA - Vet - B35 b) - b) Addition of a new specification parameter to the specification with its corresponding test method - B35 b) Changes to the quality part of the dossier: Change in the specification parameters or limits of the immediate packaging of the finished product: — addition of a new specification parameter to the specification with its corresponding test method	23/12/24
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	31/03/23
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	31/03/23